Between 15 May and 15 June 2025, Korean regulators took administrative action against three cosmetics companies for violations of the Cosmetics Act. The penalties ran from suspension of sales and advertising through to cancellation of manufacturing registration — the most severe outcome available, because it removes the ability to produce at all.
For an overseas brand manufacturing in Korea, that last penalty is the one worth reading twice. A registration cancellation does not stop at the Korean company that earned it. It stops every brand whose production sits in that facility.
Why BB cream attracts the attention
Korea regulates a specific set of claims through its functional cosmetics framework. Whitening, wrinkle improvement, and UV protection are not ordinary marketing copy — each requires review or notification before a product can be sold on that basis, along with supporting data.
BB cream sits directly on top of that framework. The category began as a blemish balm and its whole pitch is that one tube does the work of three: tone correction, coverage, and sun protection. Stack those claims and the product is asserting multiple regulated functions at once, each of which has to be individually substantiated and correctly declared.
Most enforcement in this category is not about a dangerous formula. It is about a claim the paperwork does not support, or an SPF figure carried over from a supplier’s raw data rather than tested on the finished product. The formulation passes; the file behind it does not.
The direct-purchase channel removes the checkpoint
When a product is imported conventionally, someone becomes the importer of record in the destination market. That entity is accountable for local labelling, ingredient restrictions, and safety documentation, and customs has a party to hold responsible.
Cross-border direct purchase skips that step. The parcel travels to a consumer as a personal import, and the checkpoint that would normally catch a restricted ingredient or a non-compliant claim never runs. The product is compliant in Korea and unexamined everywhere else.
This matters because ingredient restrictions genuinely diverge. A pigment or preservative used in a Korean BB cream and fully permitted there can be restricted in Southeast Asian markets operating under different annexes. Brands running a direct-to-consumer export model often assume Korean approval travels with the box. It does not.
What a brand inherits from its manufacturing partner
Brand owners tend to think of regulatory risk as something attached to their own label. In an OEM relationship, a meaningful share of it is attached to the factory.
Registration status, inspection history, and the quality management system all sit with the manufacturer. If a facility’s registration is cancelled over another client’s product, every brand in that plant faces the same production stop, and technology transfer to a replacement facility is not a two-week job. Formulation records, stability data, packaging specifications, and supplier qualifications all have to move, and the receiving plant will want to re-run its own validation.
That is the case for asking uncomfortable questions during supplier selection rather than after the contract is signed. Inspection history is a fair question. So is which regulatory workstreams the manufacturer handles and which stay with the brand — ambiguity there is where labelling and advertising violations tend to originate.
Retail buyers now ask for the file, not the sample
The change worth noting on the commercial side is what a buyer requests in a first meeting. A finished sample and a price list used to be enough to start a conversation. Increasingly, the second email asks for documentation.
The list is fairly consistent across serious retail partners:
- Full quantitative ingredient breakdown, not just the INCI list from the carton
- Finished-product SPF and broad-spectrum test reports, with the testing laboratory named
- Manufacturing site certification and current registration status
- Stability and compatibility data covering the actual pack, not a generic jar
- Claim substantiation for each regulated function the label asserts
Brands that can produce this within a few days move through vetting quickly. Brands that have to go back to the factory and negotiate for it lose weeks, and buyers read the delay as a signal about how the relationship will run under pressure.
Counterfeits and the grey channel
The direct-purchase market has a second-order problem. Because parcels bypass conventional import scrutiny, they also bypass the point where a counterfeit is most likely to be caught. Marketplaces have responded with seller verification and escrow arrangements, though the depth of those checks varies widely from platform to platform.
For a brand, the exposure is asymmetric. A counterfeit that irritates a customer’s skin generates a review, a social post, and possibly a regulator’s inquiry attached to the genuine brand name — regardless of where the product actually came from. Markets that have moved to restrict specific imported products have generally done so after exactly this kind of incident.
Batch-level traceability is the practical defence. If a brand can tie a complaint to a production lot within a day, it can separate its own product from a copy. If it cannot, it inherits every accusation made against anything carrying its name.
What to change in the launch plan
Three adjustments cover most of the exposure. Decide the destination market before finalising the claim set, so the SPF figure and tone-correction language are built against the rules that will actually apply. Assemble the documentation package during development rather than when a buyer asks, since retrospective testing on a finished batch is slower and more expensive than testing planned in. And treat manufacturer registration status as a live commercial risk to be monitored, not a box checked once at onboarding.
The regulatory direction across the region is toward more disclosure, not less. Building for that now is considerably cheaper than reformulating a hero product after a market closes to it.
“We are fielding far more questions from overseas buyers about documentation and traceability than about the formula itself, and that is a real shift from a couple of years ago. Brands entering the Korean-adjacent market are learning that an inspired-by-K-beauty positioning now comes with due-diligence expectations from their own retail partners, who want the file before they want the sample. In our experience the buyers who ask for clear ingredient disclosure and manufacturing paperwork upfront are the ones building product lines that survive past a single viral moment.” — Hyejin Cho, Digital Marketing Specialist, Marketing and Communication Team at SPSCOS